Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 27;5:1141. doi: 10.1038/s42003-022-04097-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Schematic of experimental design, including both young (3-month-old) and adult (6.5-month-old) groups. b Body mass before and after 20 days of tamoxifen treatment (40 mg kg⁻¹ day⁻¹) in 3-month-old (left, young) and 6.5-month-old (right, adult) control (n = 13 young and 10 adult), AKT-TG (n = 9 young and 11 adult), TSCmKO (n = 11 young and 8 adult) and TSC-AKT (n = 9 young and 5 adult) mice. c Muscle mass after 20 days tamoxifen treatment in young (upper) and adult (lower) mice. d Peak tetanic in vitro muscle force, normalized to 3-month-old control (sex specific), e specific force and f mean twitch profile for both fast-type EDL (upper) and slow-type SOL (lower) muscle. For e, f, n = 21, 17, 17 and 14 (EDL) and 16–17, 14, 14, and 11 (SOL) for control (Con), AKT-TG, TSCmKO, and TSC-AKT, respectively. Data are presented as mean ± SEM. Two-way ANOVAs with Sidak post hoc tests were used to compare data. For e, separate repeated measures two-way ANOVAs were used to compare between control and AKT-TG groups and between TSCmKO and TSC-AKT groups. *, **, and *** denote a significant difference between groups of P < 0.05, P < 0.01, and P < 0.001, respectively. For trends, where 0.05 < P < 0.10, p values are reported.